Zhen Wang

Zhen Wang

Auto-generated profile, based on publicly available information

Zhen Wang

Evidence-Based Practice Center, Mayo Clinic, Rochester, MN, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2014 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
JDJuan Pablo Domecq
Juan Pablo Domecq
GPGabriela Prutsky
Gabriela Prutsky
TETarig Elraiyah
Tarig Elraiyah
ZWZhen Wang
Zhen Wang
MNMohammed Nabhan
Mohammed Nabhan
MMMohammad Hassan Murad
Mohammad Hassan Murad
A compelling ethical rationale supports patient engagement in healthcare research. It is also assumed that patient engagement will lead to research findings that are more pertinent to patients’ concerns and dilemmas. However; it is unclear how to best conduct this process. In this systematic review we aimed to answer 4 key questions: what are the best ways to identify patient representatives? How to engage them in designing and conducting research? What are the observed benefits of patient engagement? What are the harms and barriers of patient engagement? We searched MEDLINE, EMBASE, PsycInfo, Cochrane, EBSCO, CINAHL, SCOPUS, Web of Science, Business Search Premier, Academic Search Premier and Google Scholar. Included studies were published in English, of any size or design that described engaging patients or their surrogates in research design. We conducted an environmental scan of the grey literature and consulted with experts and patients. Data were analyzed using a non-quantitative, meta-narrative approach. We included 142 studies that described a spectrum of engagement. In general, engagement was feasible in most settings and most commonly done in the beginning of research (agenda setting and protocol development) and less commonly during the execution and translation of research. We found no comparative analytic studies to recommend a particular method. Patient engagement increased study enrollment rates and aided researchers in securing funding, designing study protocols and choosing relevant outcomes. The most commonly cited challenges were related to logistics (extra time and funding needed for engagement) and to an overarching worry of a tokenistic engagement. Patient engagement in healthcare research is likely feasible in many settings. However, this engagement comes at a cost and can become tokenistic. Research dedicated to identifying the best methods to achieve engagement is lacking and clearly needed.

9 May 2012 in JAMA
Verified
Journal Article
Open access
PDF file
SNSydne J. Newberry
Sydne J. Newberry
SHSusanne Hempel
Susanne Hempel
AMAlicia R. Maher
Alicia R. Maher
ZWZhen Wang
Zhen Wang
JMJeremy N. V. Miles
Jeremy N. V. Miles
PSPaul G. Shekelle
Paul G. Shekelle
Review from JAMA — Probiotics for the Prevention and Treatment of Antibiotic-Associated Diarrhea — A Systematic Review and Meta-analysis

1 July 2014 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
ALAaron Leppin
Aaron Leppin
MGMichael R. Gionfriddo
Michael R. Gionfriddo
MKMaya Kessler
Maya Kessler
JBJuan P Brito
Juan P Brito
FMFrances Susanne Mair
Frances Susanne Mair
VMVictor M. Montori
Victor M. Montori
Early hospital readmissions have been recognized as a common and costly occurrence, particularly among elderly and high-risk patients. One in 5 Medicare beneficiaries is readmitted within 30 days, for example, at a cost of more than $26 billion per year.1 To encourage improvement in the quality of care and a reduction in unnecessary health expense, policymakers, reimbursement strategists, and the US government have made reducing 30-day hospital readmissions a national priority.2-4 Achieving this goal, however, requires a more complete understanding of the underlying causes of readmission.

28 September 2011 in JAMA
Verified
Journal Article
Open access
PDF file
AMAlicia Ruelaz Maher
Alicia Ruelaz Maher
MMMargaret Maglione
Margaret Maglione
SBSteven Bagley
Steven Bagley
MSMarika Suttorp
Marika Suttorp
JHJian-Hui Hu
Jian-Hui Hu
PSPaul G. Shekelle
Paul G. Shekelle
Review from JAMA — Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults — A Systematic Review and Meta-analysis

14 January 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ZWZhen Wang
Zhen Wang
TNTarek Nayfeh
Tarek Nayfeh
JTJennifer Tetzlaff
Jennifer Tetzlaff
POPeter O'Blenis
Peter O'Blenis
MMMohammad Hassan Murad
Mohammad Hassan Murad
Automated approaches to improve the efficiency of systematic reviews are greatly needed. When testing any of these approaches, the criterion standard of comparison (gold standard) is usually human reviewers. Yet, human reviewers make errors in inclusion and exclusion of references. To determine citation false inclusion and false exclusion rates during abstract screening by pairs of independent reviewers. These rates can help in designing, testing and implementing automated approaches. We identified all systematic reviews conducted between 2010 and 2017 by an evidence-based practice center in the United States. Eligible reviews had to follow standard systematic review procedures with dual independent screening of abstracts and full texts, in which citation inclusion by one reviewer prompted automatic inclusion through the next level of screening. Disagreements between reviewers during full text screening were reconciled via consensus or arbitration by a third reviewer. A false inclusion or exclusion was defined as a decision made by a single reviewer that was inconsistent with the final included list of studies. We analyzed a total of 139,467 citations that underwent 329,332 inclusion and exclusion decisions from 86 unique reviewers. The final systematic reviews included 5.48% of the potential references identified through bibliographic database search (95% confidence interval (CI): 2.38% to 8.58%). After abstract screening, the total error rate (false inclusion and false exclusion) was 10.76% (95% CI: 7.43% to 14.09%). This study suggests important false inclusion and exclusion rates by human reviewers. When deciding the validity of a future automated study selection algorithm, it is important to keep in mind that the gold standard is not perfect and that achieving error rates similar to humans may be adequate and can save resources and time.

1 November 2017 in JAMA Pediatrics
Verified
Journal Article
Closed access
PDF file
ZWZhen Wang
Zhen Wang
SWStephen P. H. Whiteside
Stephen P. H. Whiteside
LSLeslie Sim
Leslie Sim
WFWigdan Farah
Wigdan Farah
AMAllison S. Morrow
Allison S. Morrow
MMMohammad Hassan Murad
Mohammad Hassan Murad
Importance Childhood anxiety is common. Multiple treatment options are available, but existing guidelines provide inconsistent advice on which treatment to use. Objectives To evaluate the comparative effectiveness and adverse events of cognitive behavioral therapy (CBT) and pharmacotherapy for childhood anxiety disorders. Data Sources We searched MEDLINE, EMBASE, PsycINFO, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and SciVerse Scopus from database inception through February 1, 2017. Study Selection Randomized and nonrandomized comparative studies that enrolled children and adolescents with confirmed diagnoses of panic disorder, social anxiety disorder, specific phobias, generalized anxiety disorder, or separation anxiety and who received CBT, pharmacotherapy, or the combination. Data Extraction and Synthesis Independent reviewers selected studies and extracted data. Random-effects meta-analysis was used to pool data. Main Outcomes and Measures Primary anxiety symptoms (measured by child, parent, or clinician), remission, response, and adverse events. Results A total of 7719 patients were included from 115 studies. Of these, 4290 (55.6%) were female, and the mean (range) age was 9.2 (5.4-16.1) years. Compared with pill placebo, selective serotonin reuptake inhibitors (SSRIs) significantly reduced primary anxiety symptoms and increased remission (relative risk, 2.04; 95% CI, 1.37-3.04) and response (relative risk, 1.96; 95% CI, 1.60-2.40). Serotonin-norepinephrine reuptake inhibitors (SNRIs) significantly reduced clinician-reported primary anxiety symptoms. Benzodiazepines and tricyclics were not found to significantly reduce anxiety symptoms. When CBT was compared with wait-listing/no treatment, CBT significantly improved primary anxiety symptoms, remission, and response. Cognitive behavioral therapy reduced primary anxiety symptoms more than fluoxetine and improved remission more than sertraline. The combination of sertraline and CBT significantly reduced clinician-reported primary anxiety symptoms and response more than either treatment alone. Head-to-head comparisons were sparse, and network meta-analysis estimates were imprecise. Adverse events were common with medications but not with CBT and were not severe. Studies were too small or too short to assess suicidality with SSRIs or SNRIs. One trial showed a statistically nonsignificant increase in suicidal ideation with venlafaxine. Cognitive behavioral therapy was associated with fewer dropouts than pill placebo or medications. Conclusions and Relevance Evidence supports the effectiveness of CBT and SSRIs for reducing childhood anxiety symptoms. Serotonin-norepinephrine reuptake inhibitors also appear to be effective based on less consistent evidence. Head-to-head comparisons between various medications and comparisons with CBT represent a need for research in the field.